<p>In venture capital, everyone celebrates the hockey stick. The explosive growth chart. The 10x year. But experienced operators know that behind every explosive growth year is a build year that made it possible.</p>

<h2>2025 Was Our Build Year — By Design</h2>

<p>Veracor Capital is transparent about 2025. It was an intentional infrastructure year. Not because growth stalled, but because the team made deliberate strategic decisions to retool for scale:</p>

<ul> <li><strong>RIIZE STRIPS</strong> generated $3.6M in its first year (2024) as a prescription-only product. The team then made the strategic decision to pivot entirely to direct-to-consumer — a move that required rebuilding the go-to-market strategy, reformulating for DTC distribution, and preparing supply chain for nationwide retail. That work happened in 2025.</li> <li><strong>KureCare</strong> continued operating and generating revenue ($4.6M in 2025), but the focus shifted to systematizing protocols for broader deployment.</li> <li><strong>KureOS</strong> entered active development — codifying Signal-Based Medicine into an AI-powered clinical decision support platform.</li> <li><strong>The Women's Empowerment Fund</strong> was structured and opened for investment.</li> <li><strong>The Reg CF filing</strong> was prepared to open retail investor access in 2026.</li> </ul>

<h2>Build Years Are a Feature, Not a Bug</h2>

<p>Sophisticated investors understand this. The best private equity returns come from managers who invest in infrastructure before deploying growth capital — not from managers who chase top-line growth at the expense of operational readiness.</p>

<p>Amazon didn't turn a profit for years because Bezos was building logistics infrastructure. The analogy isn't perfect, but the principle is: the companies that invest in foundation before scale tend to compound more durably than those that skip this phase.</p>

<h2>What 2026 Looks Like</h2>

<p>Everything built in 2025 ships in 2026:</p>

<ul> <li>RIIZE DTC launches nationwide</li> <li>KureOS enters clinical pilots</li> <li>Reg CF opens retail investor access</li> <li>Multi-fund strategy goes fully live</li> </ul>

<p>The build year is over. The launch year is here.</p>